ECSP23088752A - Anticuerpos anti-adgre2 y usos de los mismos - Google Patents

Anticuerpos anti-adgre2 y usos de los mismos

Info

Publication number
ECSP23088752A
ECSP23088752A ECSENADI202388752A ECDI202388752A ECSP23088752A EC SP23088752 A ECSP23088752 A EC SP23088752A EC SENADI202388752 A ECSENADI202388752 A EC SENADI202388752A EC DI202388752 A ECDI202388752 A EC DI202388752A EC SP23088752 A ECSP23088752 A EC SP23088752A
Authority
EC
Ecuador
Prior art keywords
antibodies
adgre2
fragments
fusion proteins
cancers
Prior art date
Application number
ECSENADI202388752A
Other languages
English (en)
Inventor
Xingyue He
Shawn Jennings
Antara Banerjee
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP23088752A publication Critical patent/ECSP23088752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos, fragmentos de los mismos y proteínas de fusión que se unen específicamente a ADGRE2, así como métodos de preparación y uso de tales anticuerpos. Estos anticuerpos, proteínas de fusión y fragmentos de los mismos son de utilidad para el tratamiento y el diagnóstico de diversas enfermedades autoinmunes y cánceres, incluyendo, por ejemplo, leucemia mieloide aguda.
ECSENADI202388752A 2021-04-26 2023-11-23 Anticuerpos anti-adgre2 y usos de los mismos ECSP23088752A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179756P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
ECSP23088752A true ECSP23088752A (es) 2024-01-31

Family

ID=81648880

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202388752A ECSP23088752A (es) 2021-04-26 2023-11-23 Anticuerpos anti-adgre2 y usos de los mismos

Country Status (16)

Country Link
US (1) US20230018888A1 (es)
EP (1) EP4330283A1 (es)
JP (1) JP2024518776A (es)
KR (1) KR20240004287A (es)
CN (1) CN117580860A (es)
AR (1) AR125450A1 (es)
AU (1) AU2022266583A1 (es)
BR (1) BR112023020371A2 (es)
CA (1) CA3214355A1 (es)
CL (1) CL2023003174A1 (es)
CO (1) CO2023013195A2 (es)
EC (1) ECSP23088752A (es)
IL (1) IL307940A (es)
MX (1) MX2023011712A (es)
TW (1) TW202305003A (es)
WO (1) WO2022232035A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089622A1 (en) * 2022-10-25 2024-05-02 Takeda Pharmaceutical Company Limited Adgre2 chimeric receptor nk cell compositions and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703893B2 (ja) 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6719750B2 (en) 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CN100349629C (zh) 2001-09-12 2007-11-21 贝克顿迪肯森公司 用于药物传送的微针为基础的笔装置和使用该装置的方法
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
JP6296536B2 (ja) * 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ 内皮前駆細胞のマーカーおよびその使用
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
MA43282A (fr) * 2015-11-19 2018-09-26 Abbvie Stemcentrx Llc Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
CA3000514A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof

Also Published As

Publication number Publication date
MX2023011712A (es) 2023-10-12
CO2023013195A2 (es) 2023-10-19
IL307940A (en) 2023-12-01
CL2023003174A1 (es) 2024-05-24
EP4330283A1 (en) 2024-03-06
WO2022232035A1 (en) 2022-11-03
CA3214355A1 (en) 2022-11-03
AU2022266583A9 (en) 2023-10-26
AU2022266583A1 (en) 2023-10-19
AR125450A1 (es) 2023-07-19
KR20240004287A (ko) 2024-01-11
CN117580860A (zh) 2024-02-20
JP2024518776A (ja) 2024-05-02
TW202305003A (zh) 2023-02-01
BR112023020371A2 (pt) 2024-02-06
US20230018888A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CO2019013611A2 (es) Anticuerpos específicos para flt3 y sus usos
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
ECSP23088752A (es) Anticuerpos anti-adgre2 y usos de los mismos
UY35258A (es) ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS
UY38242A (es) Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos
CO2017002719A2 (es) Anticuerpos anti-glucagón
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
CR20170059A (es) ANTICUERPOS Anti-LAG3 Y FRAGMENTOS DE UNIÓN A ANTÍGENO
UY37591A (es) Conjugados de fármaco anticuerpo
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
UY35712A (es) Anticuerpos anti-prlr y uso de los mismos
UY35042A (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos.
CL2020002144A1 (es) Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143)
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CO2020005347A2 (es) Anticuerpos y conjugados de anticuerpo-fármaco específicos para cd123 y usos de los mismos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
UY36706A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
EA202092302A1 (ru) Антитела к trem-1 и их применения
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
CO2024004055A2 (es) Polipéptidos
CO2023014316A2 (es) Anticuerpos anti-clec12a y usos de los mismos